BioGaia AB’s Nomination Committee for the 2025 Annual General Meeting

BioGaia AB’s Nomination Committee for the Annual General Meeting 2025 has been appointed based on the ownership structure as of June 30, 2024.

The Nomination Committee for the Annual General Meeting 2025 has been formed in accordance with the decision of the Annual General Meeting. The Nomination Committee consists of David Dangoor (Chairman of the Nomination Committee), appointed by the largest shareholder Annwall & Rothschild Investments AB, Jacob Sellman, EQT, Jannis Kitsakis, appointed by AP4, and Thomas Brown, Premier Miton Investors. In addition, Peter Rothschild is a member of the Nomination Committee in his capacity as Chairman of the Board.

Shareholders wishing to submit proposals to the Nomination Committee are welcome to contact the Chairman of the Nomination Committee by e-mail at derd@derdangoor.com, or by letter to the address BioGaia AB, Nomination Committee, Kungsbroplan 3A, 112 27 Stockholm.

The Annual General Meeting in BioGaia AB will be held on May 7, 2025, in Stockholm.
 

Follow us:
Subscribe to BioGaia press releases here
LinkedIn here

Contacts:
Peter Rothschild, Chairman of the Board
Email: pr@biogaia.se
Phone: +46 708 30 65 40

Caroline Mofors, Chief Legal Officer
Email: cam@biogaia.se
Phone: +46 733 60 48 59

About BioGaia
BioGaia is a Swedish probiotic company that has been at the forefront of microbiome research for more than 30 years. BioGaia develops, markets, and sells probiotic products focused on gut health, immune health, and oral health. The products are sold through local distribution partners or via own distribution in over 100 markets. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap segment of Nasdaq Stockholm. biogaiagroup.com